COSA:AYA fertility preservation/Impact of cancer treatments on fertility/Table effect of cancer treatments on sperm production
From Cancer Guidelines Wiki
Fertility preservation for AYAs diagnosed with cancer: Guidance for health professionals. > COSA:AYA fertility preservation/Impact of cancer treatments on fertility/Table effect of cancer treatments on sperm production
Table 3: Effect of cancer treatments on sperm production in males
| Degree of risk | Treatment | Common usage |
|---|---|---|
| High risk: prolonged azoospermia after treatment | Total body irradiation | Bone marrow transplantation, Stem cell transplantation (BMT/SCT) |
| Testicular radiation dose > 2.5 Gy in men | Testicular cancer, ALL, NHL | |
| Testicular radiation dose ≥ 6 Gy in boys | ALL, NHL, sarcoma, germ cell tumours | |
| Protocols containing procarbazine: COPP, MOPP (83% risk) [1], MVPP (97% risk) [1], ChIVPP, ChIVPP/EVA, MOPP/ABVD, COPP/ABVD (62% risk) [1] | Hodgkin lymphoma | |
| Alkylating chemotherapy for transplantation conditioning (cyclophosphamide, busulfan, melphalan)(70% risk) [1] | BMT/SCT | |
| Any alkylating agent (eg, procarbazine, nitrogen mustard, cyclophosphamide) + TBI (80-90% risk) [1], pelvic radiation, or testicular radiation | Testicular cancer, BMT/SCT, ALL, NHL, sarcoma, neuroblastoma, Hodgkin lymphoma | |
| BEACOPP (67-80% risk) [1] | Hodgkin lymphoma | |
| Cyclophosphamide > 7.5 g/m2 | Sarcoma, NHL, neuroblastoma, ALL | |
| Cranial/brain radiation ≥ 40 Gy | Brain tumour | |
| Intermediate risk: prolonged azoospermia not common at standard dose | BEP × 2-4 cycles | Testicular cancer |
| Cumulative cisplatin dose < 400 mg/m2 | Testicular cancer | |
| Cumulative carboplatin dose ≤ 2 g/m2 | Testicular cancer | |
| Testicular radiation dose 1-6 Gy (as a result of scatter from abdominal/pelvic radiation) | Wilms tumour, neuroblastoma | |
| Low risk: temporary azoospermia after treatment | Lower dose alkylating chemotherapy: ABVD (8% risk) [1], OEPA, NOVP, CHOP, COP | Hodgkin lymphoma, NHL |
| Testicular radiation dose 0.2-0.7 Gy | Testicular cancer | |
| Very low/no risk: no effects on sperm production | Testicular radiation dose < 0.2 Gy | Multiple cancers |
| Interferon alfa | Multiple cancers | |
| Radioactive iodine | Thyroid cancer | |
| Unknown risk | Irinotecan | Colon cancer |
| Bevacizumab | Colon, non–small-cell lung cancer | |
| Cetuximab | Colon, head and neck cancer | |
| Erlotinib | Non–small-cell lung, pancreatic cancer | |
| Imatinib | Chronic myeloid leukemia, GI stromal tumor |
Source: Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer J Clin Oncol 2010 Nov 10;28(32):4831-41 [Available at http://www.ncbi.nlm.nih.gov/pubmed/20458029].
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Leader A, Lishner M, Michaeli J, Revel A. Fertility considerations and preservation in haemato-oncology patients undergoing treatment. Br J Haematol 2011 May;153(3):291-308 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21391973.